Drug Price Trends for MYORISAN

Best Wholesale Price for MYORISAN

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
MYORISAN 20MG CAP	Golden State Medical Supply, Inc.	61748-0302-11	100	704.00	7.04000	EACH	2023-06-15 - 2028-06-14	FSS
MYORISAN 20MG CAP	Golden State Medical Supply, Inc.	61748-0302-13	30	70.52	2.35067	EACH	2023-06-15 - 2028-06-14	FSS
MYORISAN 30MG CAP	Golden State Medical Supply, Inc.	61748-0303-13	30	189.74	6.32467	EACH	2023-06-15 - 2028-06-14	FSS
MYORISAN 40MG CAP	Golden State Medical Supply, Inc.	61748-0304-11	100	816.00	8.16000	EACH	2023-06-15 - 2028-06-14	FSS
MYORISAN 40MG CAP	Golden State Medical Supply, Inc.	61748-0304-13	30	78.73	2.62433	EACH	2023-06-15 - 2028-06-14	FSS

Market Dynamics and Price Forecasts for MYORISAN

Last updated: February 18, 2026

MYORISAN (isotretinoin) is a vitamin A derivative indicated for severe recalcitrant nodular acne. The drug operates within the dermatology market, facing competition from other isotretinoin formulations and alternative acne treatments. Market growth is influenced by acne prevalence, physician prescribing habits, and patient access to treatment.

What is the Current Market Size and Growth Trajectory for Isotretinoin?

The global isotretinoin market is projected to grow, driven by an increasing prevalence of severe acne globally and a rising awareness of isotretinoin's efficacy. Reports estimate the global isotretinoin market size to be valued at approximately USD 1.0 billion in 2023, with projections to reach USD 1.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.0% [1]. This growth is supported by a growing patient pool and an expanding geographic reach for the drug [1].

Key market drivers include:

• Rising Acne Prevalence: The persistent occurrence of acne, particularly severe forms, fuels demand. A study by the American Academy of Dermatology indicates that acne affects up to 50 million people annually in the United States alone [2].
• Increasing Awareness of Efficacy: Physicians and patients are increasingly recognizing isotretinoin as a potent treatment option for severe, treatment-resistant acne [3].
• Availability of Generic Formulations: The presence of multiple generic isotretinoin products intensifies market competition and can influence pricing strategies [4]. MYORISAN is a branded product.
• Advancements in Pharmaceutical Manufacturing: Improved production processes contribute to the sustained availability of isotretinoin [1].

The market is segmented by formulation (capsules, gels), indication (acne vulgaris, other dermatological conditions), and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies) [1].

Who are the Key Competitors for MYORISAN?

MYORISAN competes with both branded and generic isotretinoin products, as well as alternative therapeutic classes for acne treatment.

Direct Competitors (Isotretinoin Formulations):

• Accutane (Isotretinoin): Historically the leading branded isotretinoin product, though its market presence has shifted with the advent of generics and other brands like MYORISAN [5].
• Generic Isotretinoin: Numerous manufacturers produce generic isotretinoin, offering lower price points and contributing to market accessibility. Examples include products from Teva Pharmaceuticals, Mylan N.V. (now Viatris), and Sun Pharmaceutical Industries [4].
• Absorica (Isotretinoin): A branded isotretinoin formulation known for its unique lipid-based absorption technology, potentially offering different pharmacokinetic profiles compared to standard formulations [6].

Indirect Competitors (Alternative Acne Treatments):

• Topical Retinoids: Such as tretinoin, adapalene, and tazarotene, used for mild to moderate acne and often as maintenance therapy post-isotretinoin [7].
• Topical Antibiotics: Clindamycin and erythromycin, used for inflammatory acne [7].
• Oral Antibiotics: Doxycycline, minocycline, used for moderate to severe inflammatory acne [7].
• Hormonal Therapies: Oral contraceptives and spironolactone for female patients with hormonal acne [7].
• Other Oral Agents: Newer treatments like topical retinoid-clindamycin combinations or dapsone gel are also used [8].

The competitive landscape necessitates differentiation through product attributes, pricing, and market access strategies for MYORISAN.

What are the Pricing Dynamics and Projections for MYORISAN?

Pricing for MYORISAN is influenced by its branded status, manufacturing costs, the competitive pricing of generic isotretinoin, insurance coverage, and patient out-of-pocket costs.

Current Pricing Landscape:

• Branded vs. Generic: Branded isotretinoin products like MYORISAN generally command a premium price compared to generic equivalents. A 30-day supply of MYORISAN can range from $300 to $600 or more, depending on the dosage and pharmacy [9].
• Generic Isotretinoin Pricing: Generic isotretinoin is significantly more affordable, with a 30-day supply often costing between $50 and $150 [9]. This price disparity is a major factor influencing treatment choices, especially for uninsured or underinsured patients.
• Insurance Coverage: Insurance formularies play a critical role. Many insurance plans have tiered copays, with generics typically in lower tiers. Prior authorization requirements or step therapy protocols may be common for branded isotretinoin, pushing patients towards generics first [10].
• Patient Assistance Programs: Branded manufacturers, including potentially the makers of MYORISAN, often offer patient assistance programs or co-pay cards to reduce the financial burden for eligible patients [11].

Price Projections:

• Sustained Premium for Branded Products: MYORISAN is likely to maintain a price premium over generics due to its brand recognition and potentially proprietary formulation or delivery systems. However, this premium will be under pressure from the widespread availability and cost-effectiveness of generics [4].
• Impact of Generic Competition: The continued presence of numerous generic isotretinoin manufacturers will exert downward pressure on the overall isotretinoin market prices. MYORISAN's pricing will need to remain competitive within the branded segment to retain market share [4].
• Inflationary Trends: General pharmaceutical inflation trends may lead to incremental price increases for MYORISAN over time, similar to other prescription medications. These increases are typically in the low single digits annually [12].
• Market Share Dynamics: If MYORISAN demonstrates superior clinical outcomes or patient adherence compared to generics, it could command a more stable premium. Conversely, if clinical differentiation is marginal, price will become a more significant determinant of market share, potentially limiting price increases [3].
• Reimbursement Landscape Shifts: Changes in healthcare policy, insurance company formulary decisions, and the growth of value-based care models could influence reimbursement rates and patient access, indirectly affecting pricing strategies [10].

Estimated Price Range for MYORISAN (Per 30-day supply, retail):

• Current: $300 - $600+
• Projected (2025-2027): $330 - $680+ (accounting for modest annual price increases of 3-5%) [12].

It is important to note that these are retail price estimates. Actual patient out-of-pocket costs will vary significantly based on insurance plans, co-pays, deductibles, and the utilization of patient assistance programs.

What are the Regulatory and Patent Considerations Affecting MYORISAN?

The regulatory environment and patent status are critical for understanding MYORISAN's market exclusivity and competitive positioning.

Regulatory Landscape:

• FDA Approval: MYORISAN, like all prescription drugs in the US, is subject to rigorous review and approval by the Food and Drug Administration (FDA) for safety and efficacy [13]. The indication for severe recalcitrant nodular acne is a defined therapeutic area.
• REMS Program: Isotretinoin products, including MYORISAN, are typically subject to a Risk Evaluation and Mitigation Strategy (REMS) program. The iPLEDGE program (or its successor) was historically mandated by the FDA to manage the risks of birth defects associated with isotretinoin [14]. These programs impose strict requirements on prescribers, pharmacies, and patients, influencing prescribing patterns and patient adherence. Changes to REMS requirements can impact market access and patient uptake.
• Post-Market Surveillance: The FDA monitors the safety of approved drugs through post-market surveillance, which can lead to label changes, warnings, or, in rare cases, market withdrawal.

Patent Considerations:

• Patent Exclusivity: The primary patent protection for the original isotretinoin molecule has long expired. However, branded products like MYORISAN may hold secondary patents related to specific formulations, manufacturing processes, delivery systems, or methods of use that provide periods of market exclusivity [15].
• Patent Expiration Dates: The critical factor for MYORISAN's market trajectory is the expiration of any active patents that prevent generic manufacturers from entering the market with a bioequivalent product. Information on specific patent expiration dates for MYORISAN would typically be found in patent databases (e.g., USPTO, WIPO) and drug product labeling. Without specific patent expiration data for MYORISAN, we assume standard patent lifecycles for branded drugs.
• Generic Entry: Once all relevant patents expire, generic manufacturers can file Abbreviated New Drug Applications (ANDAs) with the FDA. Approval of an ANDA typically leads to a significant increase in competition and a sharp decline in the price of the branded product [16].
• Orphan Drug Exclusivity: Isotretinoin is not typically considered an orphan drug for acne. However, if specific formulations or novel uses were developed and approved under orphan drug designations, this could confer additional exclusivity periods [17].

The absence of strong, remaining compound patents means MYORISAN's long-term market exclusivity is primarily dependent on any secondary patents it may hold. The threat of generic competition remains a significant factor in its pricing and market strategy.

What is the Expected Impact of MYORISAN on the Dermatology Market?

MYORISAN's impact on the dermatology market is tied to its market share, pricing strategy, and contribution to patient outcomes for severe acne.

• Market Share Contribution: As a branded option in a market with established generics, MYORISAN's market share will depend on its ability to carve out a niche. This could be through physician preference for its specific formulation, targeted marketing, or patient loyalty driven by effective results and support programs [3].
• Pricing Benchmark: MYORISAN's pricing serves as a benchmark for other branded isotretinoin products. Its positioning relative to generics influences the overall pricing strategy for the isotretinoin class [9].
• Innovation Driver (Potential): If MYORISAN represents an advancement in isotretinoin formulation or delivery that offers improved patient experience or efficacy, it could encourage further innovation in the broader acne treatment landscape [6].
• Patient Access: The accessibility and affordability of MYORISAN, particularly through co-pay programs, can influence treatment adherence for patients who might otherwise struggle with the cost of branded therapy [11].
• Competition for Dermatologists' Prescribing Habits: Dermatologists have a range of isotretinoin options. MYORISAN's success hinges on convincing prescribers of its specific benefits over generics or other branded alternatives [3].

The drug's ultimate impact will be a function of its clinical performance, cost-effectiveness, and strategic market positioning in a competitive therapeutic category.

Key Takeaways

• The global isotretinoin market is projected for moderate growth, driven by acne prevalence and treatment awareness.
• MYORISAN competes with a broad spectrum of generic isotretinoin products and alternative acne therapies.
• Branded isotretinoin, including MYORISAN, commands a significant price premium over generics, a disparity influenced by insurance coverage and patient assistance programs.
• Price projections for MYORISAN anticipate modest annual increases, constrained by ongoing generic competition.
• Regulatory oversight, particularly REMS programs for isotretinoin, shapes prescribing and patient access.
• While the original isotretinoin molecule is off-patent, MYORISAN's market exclusivity relies on secondary patents related to formulation or process.

Frequently Asked Questions

1. What is the primary difference between MYORISAN and generic isotretinoin? MYORISAN is a branded product, while generic isotretinoin products are manufactured by various companies after patent expirations. Key differences can include inactive ingredients, manufacturing processes, and potentially subtle variations in absorption or side effect profiles, though regulatory standards require generics to be bioequivalent to the reference drug [16].

2. How does the REMS program affect MYORISAN prescribing? Isotretinoin REMS programs mandate strict controls for prescribers, pharmacies, and patients to mitigate risks, primarily teratogenicity. This includes patient registration, pregnancy testing, and regular consultations, which can influence prescription volume and patient adherence [14].

3. Will MYORISAN's price decrease significantly upon generic entry for its specific formulation? As isotretinoin is already widely available in generic forms, any significant price decrease for MYORISAN would likely be tied to the expiration of specific patents protecting its unique formulation or manufacturing process, allowing for direct generic competition against MYORISAN itself [15].

4. What patient assistance programs are typically available for branded isotretinoin products like MYORISAN? Branded drug manufacturers often provide co-pay assistance cards or patient savings programs to eligible individuals with commercial insurance, reducing their out-of-pocket expenses [11].

5. What are the main alternative treatments to MYORISAN for severe recalcitrant nodular acne? Besides other isotretinoin formulations, alternative treatments for severe acne include oral antibiotics (e.g., doxycycline), hormonal therapies (e.g., oral contraceptives, spironolactone for females), and in some cases, newer combination topical therapies or antibiotic treatments, though isotretinoin remains a primary choice for severe, treatment-resistant cases [7, 8].

Citations

[1] Global Market Insights. (2023). Isotretinoin Market Size, Share & COVID-19 Impact Analysis, By Formulation (Capsules, Gels), By Indication (Acne Vulgaris, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecasts 2024-2032. [2] American Academy of Dermatology Association. (n.d.). Acne. [3] Dréno, B., & Ruer-Mohring, L. (2020). Isotretinoin in the management of acne: A review of European and North American perspectives. Journal of the European Academy of Dermatology and Venereology, 34(11), 2534-2542. [4] IQVIA. (2023). The Pharmaceutical Market Outlook. [5] FDA. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). [6] Draelos, Z. D. (2013). Absorica: A novel formulation of isotretinoin. The Journal of Clinical and Aesthetic Dermatology, 6(9), 24-28. [7] Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., ... & Bhutani, T. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945-973.e33. [8] National Institute for Health and Care Excellence. (2021). Acne vulgaris: management (NICE guideline [NG198]). [9] GoodRx. (2024). Isotretinoin Prices, Coupons & Savings. (Accessed January 15, 2024). [10] Centers for Medicare & Medicaid Services. (n.d.). National Health Expenditure Data. [11] Pharmaceutical Research and Manufacturers of America. (n.d.). Patient Assistance Programs. [12] S&P Global Market Intelligence. (2023). Global Pharmaceutical Pricing Trends. [13] U.S. Food and Drug Administration. (n.d.). Drug Development Process. [14] U.S. Food and Drug Administration. (n.d.). Isotretinoin (Accutane) and Other Isotretinoin Products (Including Amnesteem, Claravis, Myorisan, etc.). [15] U.S. Patent and Trademark Office. (n.d.). Patent Search. [16] U.S. Food and Drug Administration. (n.d.). ANDA Basics. [17] U.S. Food and Drug Administration. (n.d.). Orphan Drug Designation.